Drug Trial Radar · NCT06158841
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
421
Actual
Start
May 19, 2024
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Dec 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine change in disease symptoms of etentamig compared to standard available therapies in adult participants with relapsed/refractory (R/R) MM. Etentamig is an investigational drug being developed for the treatment of R/R MM. This study is broken into 2 Arms; Arm A and Arm B. In Arm A, participants will receive etentamig as a monotherapy. In Arm B, participants will receive the standard available therapy (SAT) identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable. Around 380 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 140 sites across the world. In Arm A participants will receive etentamig as an infusion into the vein in 28 day cycles, during the 3.5 year study duration. In Arm B, participants will receive the SAT identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable, during the 3.5 year study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.
Conditions
- Multiple Myeloma
Interventions
EtentamigDrug
Intravenous (IV) Infusion
CarfilzomibDrug
IV Infusion
PomalidomideDrug
Oral Capsule
ElotuzumabDrug
IV Infusion
SelinexorDrug
Oral Tablet
BortezomibDrug
Subcutaneous or IV Injection
DexamethasoneDrug
Oral Tablet or IV Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Up to Approximately 5 Years
- Objective Response Rate (ORR)Time frame: Up to Approximately 5 Years
Locations
166 sites in 25 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham - Main /ID# 261434
Birmingham, Alabama
Mayo Clinic Hospital - Phoenix /ID# 263326
Phoenix, Arizona
Alta Bates Summit Medical Center for Research /ID# 261438
Berkeley, California
Providence - St. Jude Medical Center /ID# 262031
Fullerton, California
VA Loma Linda Healthcare System /ID# 261015
Loma Linda, California
Cedars-Sinai Medical Center /ID# 261008
Los Angeles, California
Rocky Mountain Cancer Centers - Lone Tree /ID# 278320
Lone Tree, Colorado
Mayo Clinic Hospital Jacksonville /ID# 263324
Jacksonville, Florida
Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 246230
Jacksonville, Florida
Winship Cancer Institute of Emory University /ID# 262525
Atlanta, Georgia
University of Illinois Hospital and Health Sciences System /ID# 246349
Chicago, Illinois
Rush University Medical Center /ID# 265690
Chicago, Illinois
Nancy W. Knowles Cancer Center /ID# 271361
Elmhurst, Illinois
Springfield Clinic - First /ID# 262266
Springfield, Illinois
Our Lady Of The Lake Regional Medical Center /ID# 272780
Baton Rouge, Louisiana
Center for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 263637
Bethesda, Maryland
Beth Israel Deaconess Medical Center /ID# 271535
Boston, Massachusetts
Dana-Farber Cancer Institute /ID# 261554
Boston, Massachusetts
Regents of the University of Michigan /ID# 261577
Ann Arbor, Michigan
Karmanos Cancer Institute - Detroit /ID# 266298
Detroit, Michigan
Henry Ford Hospital /ID# 262704
Detroit, Michigan
Barbara Ann Karmanos Cancer Institute - McLaren Greater Lansing /ID# 259891
Lansing, Michigan
Mayo Clinic - Rochester /ID# 246228
Rochester, Minnesota
University of Missouri Hospital /ID# 261553
Columbia, Missouri
Nebraska Cancer Specialists - Omaha - Wright Street /ID# 276772
Omaha, Nebraska
New York Cancer & Blood Specialists - Bay Shore /ID# 261524
Bay Shore, New York
New York Cancer & Blood Specialists - Lake Success Medical Oncology /ID# 262953
New Hyde Park, New York
New York Cancer and Blood Specialists - New York /ID# 262951
New York, New York
Eastchester Center for Cancer Care /ID# 262952
The Bronx, New York
University of North Carolina /ID# 259854
Chapel Hill, North Carolina
Atrium Health Levine Cancer Institute /ID# 246199
Charlotte, North Carolina
Duke University Medical Center /ID# 259694
Durham, North Carolina
University Of Cincinnati Medical Center /ID# 246415
Cincinnati, Ohio
Cleveland Clinic Main Campus /ID# 246183
Cleveland, Ohio
Oregon Medical Research Center /ID# 262335
Portland, Oregon
Medical University of South Carolina /ID# 259692
Charleston, South Carolina
University of Tennessee Health Science Center /ID# 261622
Memphis, Tennessee
Baptist Memorial Hospital /ID# 270910
Memphis, Tennessee
The West Clinic /ID# 262444
Memphis, Tennessee
Vanderbilt University Medical Center /ID# 261621
Nashville, Tennessee
Showing 40 of 166 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.